A Study of CM512 in Subjects With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
Status:
NOT_YET_RECRUITING
Trial end date:
2028-03-17
Target enrollment:
Participant gender:
Summary
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase II Study to Explore the Efficacy and Safety of CM512 Injection in Adults with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)